Husain M, Bain SC, Holst AG, et al. - Researchers designed a post hoc analysis to analyze the cardiovascular (CV) effects of semaglutide in individuals across a continuum of baseline CV risk. Researchers collected data from the s.c. and oral semaglutide phase 3a clinical trial programs according to randomized treatment (semaglutide or comparators) to evaluate time to first major adverse CV events (MACE) and its individual components. They examined semaglutide data to evaluate the impacts of treatment as a function of CV risk predicted using the CV risk prediction model. In a broad type 2 diabetes population, semaglutide decreased the risk of MACE vs comparators across the continuum of baseline CV risk.